Pioneering lab testing firm names new board member

FORT MYERS — Cancer-focused genetic testing services firm NeoGenomics has named biosciences executive Dave Daly to its board.

Daly, with a board appointment effective Nov. 10, is currently the president and COO at Singular Genomics, a next generation sequencing and multi-omics technology platform company, according to the company’s website. Prior to Singular Genomics, Daly was CEO at Thrive Earlier Detection, a liquid biopsy-focused cancer screening company acquired by Exact Sciences Corporation for $2.15 billion earlier this year.